Ruder John, Wally Meghan K, Oliverio McKell, Seymour Rachel B, Hsu Joseph R
*Department of Orthopaedic Surgery, Carolinas HealthCare System, Charlotte, NC; and†Carolinas Trauma Network Research Center of Excellence, Carolinas HealthCare System, Charlotte, NC.
J Orthop Trauma. 2017 Jun;31(6):e179-e185. doi: 10.1097/BOT.0000000000000834.
To determine opioid-prescribing practices to the orthopaedic trauma (OT) population at one Level I trauma center.
A retrospective study of discharge prescriptions for adult patients with OT. Prescription details, injury burden, and patient demographics were abstracted for patients from initial injury through a 2-month follow-up.
Level I trauma center.
PATIENTS/PARTICIPANTS: Adult patients with OT admitted over a 30-day period (n = 110).
All discharge and follow-up opioid prescriptions were recorded.
Morphine milligram equivalents (MMEs) per day, number of opioid prescriptions, type/dose of medication prescribed.
One hundred thirty-five discharge prescriptions were written for 110 patients with orthopaedic injuries during the review period. All patients received opioids at the time of discharge. The MMEs prescribed at the time of discharge was 114 mg (54-300 mg) for a mean of 7.21 days (2-36.7 days). Although patients with preinjury risk factors were prescribed discharge opioids for a similar duration (7.00 days vs. 7.30 days, P = 0.81) than those without risk factors, they were prescribed significantly more MMEs than those without (130 vs. 108, P < 0.05) and were more likely to receive extended-release and long-acting opioids than those without (42.11% vs. 21.98%).
Pain management after OT continues to be opioid-centric despite involving a population at risk. Further focus on prescriber and patient education, risk evaluation with mitigation, guideline development, and comprehensive pain management strategies are warranted in the OT population.
Prognostic Level IV. See Instructions for Authors for a complete description of levels of evidence.
确定某一级创伤中心针对骨科创伤(OT)患者的阿片类药物处方情况。
对成年OT患者出院处方的回顾性研究。从患者初始受伤至2个月随访期间,提取处方细节、损伤负担和患者人口统计学信息。
一级创伤中心。
患者/参与者:30天内收治的成年OT患者(n = 110)。
记录所有出院及随访时的阿片类药物处方。
每日吗啡毫克当量(MME)、阿片类药物处方数量、所开药物的类型/剂量。
在回顾期内,为110例骨科损伤患者开具了135份出院处方。所有患者出院时均接受了阿片类药物治疗。出院时开具的MME为114毫克(54 - 300毫克),平均用药7.21天(2 - 36.7天)。尽管有受伤前危险因素的患者出院时开具阿片类药物的时长与无危险因素的患者相似(7.00天对7.30天,P = 0.81),但他们所开具的MME显著多于无危险因素的患者(130对108,P < 0.05),且比无危险因素的患者更有可能接受缓释和长效阿片类药物(42.11%对21.98%)。
尽管涉及高危人群,但OT后的疼痛管理仍然以阿片类药物为中心。对于OT患者,有必要进一步关注开处方者和患者教育、风险评估与缓解、指南制定以及全面的疼痛管理策略。
预后IV级。有关证据水平的完整描述,请参阅作者须知。